The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies/Entities benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns. There is no assurance that the investment objective of the Scheme will be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 5.16% | 19.1% | 18.65% | 13.11% | N/A | 19.31% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 10.6% | 69.03% | 98.29% | 85.24% | N/A | 333.32% |
| Rank within category | 3/19 | 5/18 | 8/18 | 8/18 | 5/17 | 5/14 | 4/12 | 5/10 | 5/9 | N/A | N/A |
| Sector Funds | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | N/A | 6.39% | 73.92% | 26.58% | -11.81% | 34.04% | 39.12% | -3.39% | 13.44% |
| Q1 returns | N/A | 3.8% | -3.02% | -1.2% | -6.93% | -5.11% | 9.57% | -7.66% | -0.99% |
| Q2 returns | N/A | -6.18% | 32.16% | 19.42% | -10.39% | 15.77% | 4.52% | 4.49% | 15.27% |
| Q3 returns | N/A | 0.87% | 24.08% | 5.75% | 9.17% | 12.02% | 20.04% | -1.08% | 3.25% |
| Q4 returns | -3.66% | 8.3% | 9.37% | 1.44% | -3.15% | 8.92% | 1.2% | 1.23% | -3.73% |
1% on or before 30D, NIL after 30D
| Alpha | 0.0413781 |
| Beta | 0.9462 |
| Sharpe Ratio | 0.29866 |
| Sortino Ratio | 0.644852 |
| R-Squared | 0.9459 |
| Tracking Error | 0.9442 |
| Downside Risk | 16.7703 |
| Std. Deviation (Annualised) | 14.0003 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth Current | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.15% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.79% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.80% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.62% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.51% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.84% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.78% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.76% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.39% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.39% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 3.32% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.23% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.01% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.94% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.90% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.69% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.63% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.39% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 2.35% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.27% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.00% |
| Molbio Diagnostics Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 1.77% |
| Symbiotec Pharmalab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.60% |
| Neogen Chemicals Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.50% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.93% |
| TREPS | Cash & Cash Equivalents and Net Assets | 0.57% | |
| Deepak Nitrite Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.40% |
| Mirae Asset Liquid Fund-Direct Plan-Growth | Domestic Mutual Funds Units | 0.01% | |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 0.00% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.55% | |
| Total | 100.00% | ||
Mr. Kasera has professional experience of more than 9 years and his primary responsibility includes Investment Analysis & Research. Prior to this assignment, he was associated with Axis Capital Ltd. as an Equity Research Analyst. He has also been associated with Edelweiss Broking Ltd.
Mr. Tanmay Mehta has over 12 years of experience primarily into equity research. He has been associated with the AMC since Jan 2021. Prior to this, Mr. Mehta has worked across Institutional Equity Research and Investment Banking Functions at SBI Capital Markets. He is a Chartered Accountant and has also cleared CFA (US).
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
